Abstract

After the introduction of the pertussis vaccine the number of cases decreased substantially, albeit, the disease remains present affecting mostly young infants in whom it causes severe complications, adolescents and adults. Adults are the main reservoir of Bordetella pertussis and serve as vehicle of transmission reservoir to infants. The new pertussis vaccines, manufactured for adolescents and adults, have good immunogenicity, safety and efficacy (92%) profile. The introduction of this vaccine into a universal vaccination program for adolescents and adults, would decrease the incidence of the disease in this population and more importantly, transmission of the microorganism to infants